EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

A randomised clinical trial testing the safety of and metabolic responses to short-term duodenal infusion of recombinant RORDEP1 in healthy men

Joachim Gæde, Yong Fan, Liwei Lyu, Lærke Smidt Gasbjerg, Peter Rossing, Bolette Hartmann, Jens Juul Holst, Asger B Lund, Filip K Knop, Oluf Pedersen

Diabetologia · 2026

DOI: 10.1007/s00125-026-06751-0 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetologia, 2026. Verfasst von Joachim Gæde und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Metabolic Research, Herlev and Gentofte University Hospital, University of Copenhagen, Hellerup, Denmark. Hauptthemen laut MEDLINE: Duodenum. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk Fonden, European Foundation for the Study of Diabetes, Copenhagen University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims/hypothesis RUMTOR-derived peptides (RORDEPs) 1 and 2 are polypeptides synthesised by specific strains of the human gut commensal Ruminococcus torques. Preclinical studies have shown that RORDEPs lower blood glucose via an impact on plasma incretins and an improvement of hepatic insulin sensitivity. In a randomised, placebo-controlled, crossover trial, we here explore the safety and tolerability of, as well as any metabolic responses to, a duodenal infusion of recombinant RORDEP1 (r-RORDEP1) given to healthy men after oral intake of a liquid mixed meal.

Methods

Seventeen healthy, normal-weight men between 18 and 35 years of age were randomised through block randomisation to receive either r-RORDEP1 or placebo as the initial intervention at Gentofte Hospital, Denmark. Exclusion criteria were use of any form of medication, use of antibiotics during the 3 months before intervention, lactose intolerance, smoking, alcohol or drug abuse, or the use of probiotics or creatine as dietary supplements during the study period. Blocks were created prior to trial initiation. Both participants and investigators were blinded to treatment. Following intake of a standardised liquid meal, r-RORDEP1 was given via a naso-duodenal tube as an initial bolus of 0.0108 mg/kg body weight followed by a continuous infusion of 0.25 µg kg −1 min −1 for 170 min. Primary outcomes were changes in plasma concentrations of incretins and peptide YY, while secondary endpoints were safety and tolerability, and changes in plasma insulin, C-peptide and glucose.

Results

All 17 participants completed the trial. Duodenal infusion of r-RORDEP1 was well tolerated and without changes in biochemical measures of haematological, liver or renal functions. Compared with placebo, the bolus of r-RORDEP1 induced an early (at 15 or 30 min) rise in plasma glucagon-like peptide-1, insulin and C-peptide ( q =0.001, q =0.001 and q =0.003, respectively) and a decline in plasma gastric inhibitory polypeptide and glucose ( q =0.02 and q =0.006, respectively), while also increasing whole-body insulin sensitivity as measured with the Matsuda index of insulin sensitivity ( p =0.049). Conclusions/interpretation Short-term duodenal infusion of r-RORDEP1 is safe and well tolerated and elicits changes in plasma incretins, insulin and glucose, and a measure of whole-body insulin sensitivity, aligning with findings in rodents, supporting the hypothesis that RORDEPs hold a role in impacting host metabolism.

Trial registration

ClinicalTrials.gov NCT06923839 Funding EFSD/Lilly European Diabetes Research Programme 2021, RUCILP F-19235-01-64 - NNF21SA0070428 grant and NNF23SA0084103 grant, the latter two from the Novo Nordisk Foundation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DuodenumHumansMaleAdultYoung AdultBlood GlucoseAdolescentCross-Over StudiesInsulinGlucagon-Like Peptide 1Recombinant ProteinsC-PeptideIncretinsInsulin ResistanceGastric Inhibitory Polypeptide

Stichwörter der Autor:innen

GIPGLP-1GlucoseInsulinMetabolismMicrobiomeRORDEP1

Substanzen

Blood GlucoseInsulinGlucagon-Like Peptide 1Recombinant ProteinsC-PeptideIncretinsGastric Inhibitory Polypeptide

Autor:innen und Institutionen

  • Center for Clinical Metabolic Research, Herlev and Gentofte University Hospital, University of Copenhagen, Hellerup, Denmark.
  • Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Steno Diabetes Center Copenhagen, Herlev, Denmark.
  • Novo Nordisk A/S, Bagsværd, Denmark.
  • Center for Clinical Metabolic Research, Herlev and Gentofte University Hospital, University of Copenhagen, Hellerup, Denmark. Oluf@sund.ku.dk.

Förderung

  • Novo Nordisk Fonden
  • European Foundation for the Study of Diabetes
  • Copenhagen University

Zitieren

APA

Gæde, J., Fan, Y., Lyu, L., Gasbjerg, L. S., Rossing, P., Hartmann, B., Holst, J. J., Lund, A. B., Knop, F. K., & Pedersen, O. (2026). A randomised clinical trial testing the safety of and metabolic responses to short-term duodenal infusion of recombinant RORDEP1 in healthy men. Diabetologia. https://doi.org/10.1007/s00125-026-06751-0

Vancouver

Gæde J, Fan Y, Lyu L, Gasbjerg LS, Rossing P, Hartmann B, et al. A randomised clinical trial testing the safety of and metabolic responses to short-term duodenal infusion of recombinant RORDEP1 in healthy men. Diabetologia. 2026. doi:10.1007/s00125-026-06751-0

BibTeX
@article{Gde2026,
  author = {Gæde, Joachim and Fan, Yong and Lyu, Liwei and Gasbjerg, Lærke Smidt and Rossing, Peter and Hartmann, Bolette and Holst, Jens Juul and Lund, Asger B and Knop, Filip K and Pedersen, Oluf},
  title = {A randomised clinical trial testing the safety of and metabolic responses to short-term duodenal infusion of recombinant RORDEP1 in healthy men},
  journal = {Diabetologia},
  year = {2026},
  doi = {10.1007/s00125-026-06751-0}
}
Kostenlos starten →